GlassScriptPhysician profile
Robert H Neumayr
NPI 1316924681
$1,426.20
in general payments reported to CMS, 2019-2025
14 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $11.24 · 2021: $147 · 2022: $189 · 2023: $320 · 2024: $277 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $299.97 | 2019-2024 | Amplatzer Amulet, Jot Dx, Perclose Prostyle |
| Abiomed | $264.17 | 2021-2025 | Impella |
| Amgen INC. | $184.85 | 2023-2025 | Repatha, Repatha |
| Heartflow, INC. | $148.62 | 2025 | |
| Boston Scientific Corporation | $148.11 | 2023 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Actelion Pharmaceuticals US, INC. | $133.55 | 2022 | |
| Biotronik INC. | $62.26 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.45 | 2024-2025 | Camzyos, Eliquis |
| Pfizer INC. | $33.52 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $23.68 | 2023 | |
| Cardiovascular Systems INC. | $22.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.93 | 2022 | |
| Cardiva Medical, INC. | $17.84 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Getinge USA Sales, LLC | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Neumayr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.